Adverse events in 10% or more of patients
| . | B-cell malignancies/AML continuous dosing . | B-cell malignancies intermittent dosing . | AML intermittent dosing . | Total N = 40 . | |||||
|---|---|---|---|---|---|---|---|---|---|
| 50 mg (n = 8) . | 100 mg (n = 8) . | 100 mg (n = 3) . | 150 mg (n = 3) . | 200 mg (n = 1) . | 100 mg (n = 3) . | 150 mg (n = 4) . | 200 mg (n = 10) . | Total (N = 40) . | |
| Diarrhea | 2 (25.0) | 1 (12.5) | 1 (33.3) | 1 (33.3) | 0 | 1 (33.3) | 1 (25.0) | 5 (50.0) | 12 (30.0) |
| Nausea | 2 (25.0) | 1 (12.5) | 1 (33.3) | 0 | 1 (100.0) | 0 | 1 (25.0) | 4 (40.0) | 10 (25.0) |
| Anemia | 2 (25.0) | 0 | 0 | 0 | 1 (100.0) | 1 (33.3) | 2 (50.0) | 3 (30.0) | 9 (22.5) |
| Fatigue | 0 | 2 (25.0) | 1 (33.3) | 0 | 0 | 1 (33.3) | 1 (25.0) | 4 (40.0) | 9 (22.5) |
| Constipation | 1 (12.5) | 1 (12.5) | 0 | 1 (33.3) | 0 | 0 | 2 (50.0) | 2 (20.0) | 7 (17.5) |
| Anorexia | 0 | 0 | 0 | 1 (33.3) | 0 | 0 | 0 | 6 (60.0) | 7 (17.5) |
| Dizziness | 1 (12.5) | 1 (12.5) | 0 | 1 (33.3) | 1 (100.0) | 0 | 1 (25.0) | 1 (10.0) | 6 (15.0) |
| Dyspnea | 1 (12.5) | 1 (12.5) | 0 | 0 | 0 | 0 | 1 (25.0) | 2 (30.0) | 6 (15.0) |
| Sepsis | 0 | 1 (12.5) | 0 | 0 | 0 | 0 | 2 (50.0) | 2 (20.0) | 5 (12.5) |
| Vomiting | 1 (12.5) | 1 (12.5) | 0 | 0 | 1 (100.0) | 0 | 1 (25.0) | 1 (10.0) | 5 (12.5) |
| Chills | 1 (12.5) | 0 | 0 | 0 | 0 | 0 | 1 (25.0) | 2 (20.0) | 4 (10.0) |
| Epistaxis | 0 | 0 | 0 | 0 | 0 | 0 | 2 (50.0) | 2 (20.0) | 4 (10.0) |
| Hypertension | 1 (12.5) | 1 (12.5) | 0 | 1 (33.3) | 0 | 0 | 0 | 1 (10.0) | 4 (10.0) |
| Hypotension | 1 (12.5) | 1 (12.5) | 0 | 0 | 0 | 0 | 1 (25.0) | 1 (10.0) | 4 (10.0) |
| Neutropenia | 0 | 0 | 0 | 0 | 0 | 1 (33.3) | 1 (25.0) | 2 (20.0) | 4 (10.0) |
| Pyrexia | 0 | 1 (12.5) | 0 | 0 | 0 | 2 (66.7) | 1 (25.0) | 0 | 4 (10.0) |
| . | B-cell malignancies/AML continuous dosing . | B-cell malignancies intermittent dosing . | AML intermittent dosing . | Total N = 40 . | |||||
|---|---|---|---|---|---|---|---|---|---|
| 50 mg (n = 8) . | 100 mg (n = 8) . | 100 mg (n = 3) . | 150 mg (n = 3) . | 200 mg (n = 1) . | 100 mg (n = 3) . | 150 mg (n = 4) . | 200 mg (n = 10) . | Total (N = 40) . | |
| Diarrhea | 2 (25.0) | 1 (12.5) | 1 (33.3) | 1 (33.3) | 0 | 1 (33.3) | 1 (25.0) | 5 (50.0) | 12 (30.0) |
| Nausea | 2 (25.0) | 1 (12.5) | 1 (33.3) | 0 | 1 (100.0) | 0 | 1 (25.0) | 4 (40.0) | 10 (25.0) |
| Anemia | 2 (25.0) | 0 | 0 | 0 | 1 (100.0) | 1 (33.3) | 2 (50.0) | 3 (30.0) | 9 (22.5) |
| Fatigue | 0 | 2 (25.0) | 1 (33.3) | 0 | 0 | 1 (33.3) | 1 (25.0) | 4 (40.0) | 9 (22.5) |
| Constipation | 1 (12.5) | 1 (12.5) | 0 | 1 (33.3) | 0 | 0 | 2 (50.0) | 2 (20.0) | 7 (17.5) |
| Anorexia | 0 | 0 | 0 | 1 (33.3) | 0 | 0 | 0 | 6 (60.0) | 7 (17.5) |
| Dizziness | 1 (12.5) | 1 (12.5) | 0 | 1 (33.3) | 1 (100.0) | 0 | 1 (25.0) | 1 (10.0) | 6 (15.0) |
| Dyspnea | 1 (12.5) | 1 (12.5) | 0 | 0 | 0 | 0 | 1 (25.0) | 2 (30.0) | 6 (15.0) |
| Sepsis | 0 | 1 (12.5) | 0 | 0 | 0 | 0 | 2 (50.0) | 2 (20.0) | 5 (12.5) |
| Vomiting | 1 (12.5) | 1 (12.5) | 0 | 0 | 1 (100.0) | 0 | 1 (25.0) | 1 (10.0) | 5 (12.5) |
| Chills | 1 (12.5) | 0 | 0 | 0 | 0 | 0 | 1 (25.0) | 2 (20.0) | 4 (10.0) |
| Epistaxis | 0 | 0 | 0 | 0 | 0 | 0 | 2 (50.0) | 2 (20.0) | 4 (10.0) |
| Hypertension | 1 (12.5) | 1 (12.5) | 0 | 1 (33.3) | 0 | 0 | 0 | 1 (10.0) | 4 (10.0) |
| Hypotension | 1 (12.5) | 1 (12.5) | 0 | 0 | 0 | 0 | 1 (25.0) | 1 (10.0) | 4 (10.0) |
| Neutropenia | 0 | 0 | 0 | 0 | 0 | 1 (33.3) | 1 (25.0) | 2 (20.0) | 4 (10.0) |
| Pyrexia | 0 | 1 (12.5) | 0 | 0 | 0 | 2 (66.7) | 1 (25.0) | 0 | 4 (10.0) |
Data presented as n (%).